Evidence map›Paper›PMID 30427997›Full record

Trial reportJAMA cardiology2018

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.

Daniel Lindholm, Stefan K James, Katja Gabrysch, Robert F Storey, Anders Himmelmann, Christopher P Cannon, Kenneth W Mahaffey, Philippe Gabriel Steg, Claes Held, Agneta Siegbahn and 1 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00391872 (A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes), which is not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00391872 phase3completednot on this map

A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]

TypeinterventionalSponsorAstraZenecaRan2006 to 2009Enrolled18,624ConditionsAcute Coronary SyndromeArmsTicagrelor, Clopidogrel
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Effect of Premature Acute Coronary Syndrome on Ocular Hemodynamics.International journal of medical sciences · 2025
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Daniel LindholmDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
Stefan K JamesDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
Katja GabryschUppsala Clinical Research Center, Uppsala, Sweden.
Robert F StoreyDepartment of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom.
Anders HimmelmannAstraZeneca Research and Development, Mölndal, Sweden.
Christopher P CannonCardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
Kenneth W MahaffeyStanford Center for Clinical Research, Stanford School of Medicine, Stanford, California.
Philippe Gabriel StegAssistance Publique-Hôpitaux de Paris; Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France.
Claes HeldDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
Agneta SiegbahnUppsala Clinical Research Center, Uppsala, Sweden.
Lars WallentinDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Mortality remains at about 5% within a year after an acute coronary syndrome event. Prior studies have assessed biomarkers in relation to all-cause or cardiovascular deaths but not across multiple causes. Objective: To assess if different biomarkers provide information about the risk for all-cause and cause-specific mortality. Design, Setting, and Participants: The Platelet Inhibition and Patient Outcomes (PLATO) trial randomized 18 624 patients with acute coronary syndrome to ticagrelor or clopidogrel from October 2006 through July 2008. In this secondary analysis biomarker substudy, 17 095 patients participated. Main Outcomes and Measures: Death due to myocardial infarction, heart failure, sudden cardiac death/arrhythmia, bleeding, procedures, other vascular causes, and nonvascular causes, as well as all-cause death. Exposures: At baseline, levels of cystatin-C, growth differentiation factor-15 (GDF-15), high-sensitivity C-reactive protein, high-sensitivity troponin I and T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were determined. Results: The median (interquartile range) age of patients was 62.0 (54.0-71.0) years. Of 17 095 patients, 782 (4.6%) died during follow-up. The continuous associations between biomarkers and all-cause and cause-specific mortality were modeled using Cox models and presented as hazard ratio (HR) comparing the upper vs lower quartile. For all-cause mortality, NT-proBNP and GDF-15 were the strongest markers with adjusted HRs of 2.96 (95% CI, 2.33-3.76) and 2.65 (95% CI, 2.17-3.24), respectively. Concerning death due to heart failure, NT-proBNP was associated with an 8-fold and C-reactive protein, GDF-15, and cystatin-C, with a 3-fold increase in risk. Regarding sudden cardiac death/arrhythmia, NT-proBNP was associated with a 4-fold increased risk and GDF-15 with a doubling in risk. Growth differentiation factor-15 had the strongest associations with other vascular and nonvascular deaths and was possibly associated with death due to major bleeding (HR, 4.91; 95% CI, 1.39-17.43). Conclusions and Relevance: In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death. Growth differentiation factor-15 had the strongest associations with death due to other vascular or nonvascular causes and possibly with death due to bleeding. Trial Registration: ClinicalTrials.gov Identifier: NCT00391872.

Indexed as

Acute Coronary SyndromeAgedBiomarkersCause of DeathC-Reactive ProteinEuropeFemaleFollow-Up StudiesGrowth Differentiation Factor 15HumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPlatelet Aggregation InhibitorsPrognosisBiomarkersC-Reactive ProteinGDF15 protein, humanGrowth Differentiation Factor 15Natriuretic Peptide, BrainPeptide FragmentsPlatelet Aggregation Inhibitorspro-brain natriuretic peptide (1-76)Protein PrecursorsTroponin T

Identifiers

PMID30427997
PMCPMC6583102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.